Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Venclexta (venetoclax)
i
Other names:
ABT-199, RG 7601, GDC-0199, RG7601, RG-7601, GDC 0199, A-1195425.0, ABT199, ABT 199, RO-5537382, ABT-0199
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(416)
News
Trials
Company:
AbbVie, Roche, Walter and Eliza Hall Institute
Drug class:
Bcl2 inhibitor
Related drugs:
‹
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
BP1002 (0)
FID-007 (0)
GX 15-070 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
paclitaxel (178)
albumin-bound paclitaxel (67)
ABT 263 (19)
APG-1252 (8)
APG-2575 (7)
micellar paclitaxel (3)
APG1244 (2)
AR160 (2)
BGB-11417 (2)
ABBV-167 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
ABBV-453 (0)
AZD0466 (0)
AZD4320 (0)
BGB-21447 (0)
Bcl-2 Family Inhibitors (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
FCN-338 (0)
FCN-683 (0)
oblimersen (0)
KLTi (0)
L105 (0)
LP-108 (0)
LP-118 (0)
liposomal paclitaxel (0)
MRX34 (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
S65487 (0)
SPC2996 (0)
TQB3909 (0)
TW-37 (0)
ZN-d5 (0)
BP1002 (0)
FID-007 (0)
GX 15-070 (0)
ANG1005 (0)
PNT2258 (0)
ONT-701 (0)
›
Associations
(416)
News
Trials
Search handles
@AaronGoodman33
@Abdallah81MD
@AdrienContejean
@AlkaliDr
@Anand_88_Patel
@AuclairDan
@CLachowiez
@CyclingDoctor
@DrHKantarjian
@DrRakeshPopat
@Dr_Ivanoncologo
@ErikaHamilton9
@FadiHaddad_MD
@Fer_martinmoro
@HadidiSamer
@HenrychihangFu1
@LeukDocJZ
@NicholasShortMD
@NitinJainMD
@PatelOncology
@RenoHemonc
@SCTNB
@SLentzsch
@TalhaBadarMD
@TapKadia
@VivekSubbiah
@aditishasMD
@chadinabhan
@chanyooncheah
@doctorpemm
@drkpavithran
@drsangeetmd
@fernandbteich
@hemedoc
@j_marquet
@jayastuMD
@jeff_sharman
@kevinpunie
@majorajay
@michaelwangmd
@mtmdphd
@n_gangat
@scserendipity1
@smbenlazar
@syed_abutalibmd
@tobyeyre82
@tomleblancMD
Search handles
@AaronGoodman33
@Abdallah81MD
@AdrienContejean
@AlkaliDr
@Anand_88_Patel
@AuclairDan
@CLachowiez
@CyclingDoctor
@DrHKantarjian
@DrRakeshPopat
@Dr_Ivanoncologo
@ErikaHamilton9
@FadiHaddad_MD
@Fer_martinmoro
@HadidiSamer
@HenrychihangFu1
@LeukDocJZ
@NicholasShortMD
@NitinJainMD
@PatelOncology
@RenoHemonc
@SCTNB
@SLentzsch
@TalhaBadarMD
@TapKadia
@VivekSubbiah
@aditishasMD
@chadinabhan
@chanyooncheah
@doctorpemm
@drkpavithran
@drsangeetmd
@fernandbteich
@hemedoc
@j_marquet
@jayastuMD
@jeff_sharman
@kevinpunie
@majorajay
@michaelwangmd
@mtmdphd
@n_gangat
@scserendipity1
@smbenlazar
@syed_abutalibmd
@tobyeyre82
@tomleblancMD
Filter by
Latest
8ms
#ICYMI the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/PDtssjLQyN @OHSUSOM #leuSM (@BCD_AACR)
8 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
8ms
GLOW study: Frail CLL patients treated with ibrutinib+venetoclax have a better PFS regardless of MRD status than patients receiving chlorambucil+obinutuzumab. Ibrutinib + venetoclax should be the preferred regimen for this patient population @JCO_ASCO https://t.co/slXTGVy0ZX (@SLentzsch)
8 months ago
Clinical
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)
8ms
Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML - @DrHKantarjian #cancer #leukemia #MDAndersoncancercenter #researchers #venetoclax #aml #oncology #drugs #oncodaily https://t.co/xblGnHD2vX (@oncodaily)
8 months ago
Clinical
|
Venclexta (venetoclax)
8ms
@MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal https://t.co/J2sUGN9nVh #leusm (@DrHKantarjian)
8 months ago
Clinical
|
Venclexta (venetoclax)
8ms
Respectfully disagree, we have also quite some examples of huge PFS improvement with OS detriment. Detriment, not even no effect, but pernicious effect. Examples: PI3K inhibitors in CLL/FL, venetoclax in MM. Can't guarantee you're benefiting patients just because PFS is extended (@Ivaj960612)
8 months ago
Clinical
|
Venclexta (venetoclax)
8ms
➡️ Check out our latest paper 📃 just out in @BloodJournal analyzing the outcomes of patients with Newly Dx AML having Splicing Factor gene mutations 🧬and the impact of Venetoclax based regimens 💊 @ CDDiNardo @DrHKantarjian @garciamanero @sanamloghavi @MDAndersonNews #leusm https://t.co/zDVTSmk4ci (@jayastuMD)
8 months ago
Clinical
|
Venclexta (venetoclax)
9ms
Similar findings with Venetoclax in t 11:14 myeloma , amazing how fast the light chains drop! (@RenoHemonc)
9 months ago
Venclexta (venetoclax)
9ms
From the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/mwHChay9AJ @OHSUSOM #leuSM (@BCD_AACR)
9 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
9ms
#17ICML | @tobyeyre82 (@OUHospitals) discusses the results of a MAIC of venetoclax vs. pirtobrutinib for patients with R/R CLL previously treated with a covalent BTK inhibitor: 🎥 https://t.co/w2TCvto7Im @icmlugano #CLLsm #LeuSM #HemOnc (@VJHemOnc)
9 months ago
Clinical
|
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
9ms
"True research begins AFTER #FDA approval of the drug" - @DrHKantarjian highlighted by @Daver_Leukemia A lot of work to be done after drugs are approved to optimize dosing & reduce the risk of AEs while maintaining efficacy, such as with #venetoclax #leusm (@FadiHaddad_MD)
9 months ago
Clinical • FDA event
|
Venclexta (venetoclax)
9ms
Our @CULymphoma lead Dr. @mana1981 contributed to a multicenter study of venetoclax in relapsed mantle cell lymphoma, now published @BloodAdvances. #lymsm cc @YazeedSawalha @othman_salim @PallawiTorkaMD @BrianHill_MDPhD https://t.co/v47FuVAw0z (@CULymphoma)
9 months ago
Clinical
|
Venclexta (venetoclax)
9ms
#ICYMI— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/QqtrVrDF4l @OHSUSOM #leuSM (@BCD_AACR)
9 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
9ms
Debatable and not what patients told/tell us. My mother was recently on AML (Azacitadine/Venetoclax). I was keen for her to stop (Bone marrow CR) she wanted to remain on therapy. She was incredibly keen to stay on therapy. This study will start to address de-escalation IMO (@scserendipity1)
9 months ago
Clinical
|
Venclexta (venetoclax)
9ms
Key Paper in treatment of Older AML ➡️out in @AjHematology https://t.co/Wa9gO2kET0 Incorporation of venetoclax-based therapy & increased utilization of Allo SCT has led to higher rates of quality remissions & significant improvement in OS for patients aged > 60 years. @Tapkadia (@DrHKantarjian)
9 months ago
Clinical
|
Venclexta (venetoclax)
9ms
@Othman_Al_Sawaf berichtet, in welchen Punkten #Pirtobrutinib bei #rrCLL gegenüber #Venetoclax nicht unterlegen ist: https://t.co/TWJBmF82d1 #Hämatologie #EHA23 @UniCologne @TheCrick @uclcancer @SwantonLab (@MT_Onkologie)
9 months ago
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
9ms
A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/p3FEtJd5Jn @OHSUSOM #leuSM (@BCD_AACR)
9 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
9ms
Day 5 - a provocative study of low-dose decitabine weekly + weekly venetoclax in HR-MDS & AML #leusm #mdssm https://t.co/3xYbQKWamb (@Anand_88_Patel)
9 months ago
Venclexta (venetoclax) • decitabine
9ms
Excited to see our work published in Clinical Cancer Research on our metronomic, low dose decitabine+venetoclax in MDS and AML! https://t.co/X7CDh3dfmb Thank you to @MendelGoldfing1 @Amitvermamds @Saunthararajah for making this possible (@LavidDevitz)
9 months ago
Clinical
|
Venclexta (venetoclax) • decitabine
9ms
Wie das Sechs-Jahres-Update der #CLL14-Studie den Stellenwert von #Venetoclax plus #Obinutuzumab bei #CLL untermauert, verrät @Othman_Al_Sawaf auf dem #EHA23. Das komplette Interview findet ihr auf https://t.co/QRjgnyBZRD #Hämatologie @UniCologne @TheCrick @uclcancer @SwantonLab (@MT_Onkologie)
9 months ago
Interview
|
Venclexta (venetoclax) • Gazyva (obinutuzumab)
10ms
Pleased to share @fredhutch results of #venetoclax and #ibrutinib in relapsed follicular lymphoma at #17ICML. #Zanubrutinib Rosewood study update also supports use of #BTK inhibitor in FL. @Rcl14L @mshadman @KatieLaiMD_MPH @DunleavyKieron #lymsm #17ICML (@UjjaniC)
10 months ago
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
10ms
Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJYaW (@DeLionofPunjab)
10 months ago
Venclexta (venetoclax) • Imbruvica (ibrutinib)
10ms
Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features @Prasshmehta @DrPMPGI @IndianYoungOnco https://t.co/AR0XDDJqlo (@DeLionofPunjab)
10 months ago
Venclexta (venetoclax) • Imbruvica (ibrutinib)
10ms
First antiCD19 CART liso-cel results in r/r CLL (TRANSCEND CLL 004), presented by Dr Tanya Siddiqi CR/CRi in 18% in pts with r/r CLL after BTKi/venetoclax failure! High uMRD rates in both blood (63%) and marrow (59%) #17ICML (@Fer_martinmoro)
10 months ago
Clinical
|
Venclexta (venetoclax) • Breyanzi (lisocabtagene maraleucel)
10ms
#EHA2023 | Daniela Cilloni: conferme per venetoclax anche in pazienti unfit alla chemioterapia nella leucemia mieloide acuta #AML @EHA_Hematology (@EmatoInfo)
10 months ago
Venclexta (venetoclax)
10ms
CONGRESS|#17ICML @michaelwangmd, @MDAndersonNews summarizes the phase II WINDOW-2 trial results on chemo-free induction with ibrutinib-rituximab-venetoclax (IRV) followed by R-hyperCVAD/MTX in young pts with untreated MCL. IRV induced deep responses and was safe #lymsm #lymphoma (@lymphomahub)
10 months ago
Clinical • P2 data
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab)
10ms
AML with IDH mutation is more sensitive to venetoclax. Any possibility of performing BH3 profiling to see if Bcl2 dependent? (@MichaelodwyerMD)
10 months ago
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax)
10ms
A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies— by @CLachowiez et al. https://t.co/eCADNqPNTX @OHSUSOM #leuSM (@BCD_AACR)
10 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
10ms
Important future question: Venetoclax or Pirtobrutinib after a covalent BTKi? #EHA2023 #CLL #venetoclax #pirtobrutinib (@tobyeyre82)
10 months ago
Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
10ms
My #EHA2023 highlights: 1. @Othman_Al_Sawaf reporting the up date of the #CLL14 trial. Continued benefit for #venetoclax plus #obinutuzumab in 1L treatment of #CLL. (@HallekMichael)
10 months ago
Venclexta (venetoclax) • Gazyva (obinutuzumab)
10ms
Aza/Ven/Mag phase I/II in AML. My thinking; too toxic for HR MDS? Presentation by Naval Daver #EHA2023 (@KordastiL)
10 months ago
P1/2 data
|
Venclexta (venetoclax) • azacitidine
10ms
CONGRESS #EHA2023 | @PratzKW @PennCancer shares long term follow-up data from VIALE-A, suggesting venetoclax can positively impact health-related quality of life in elderly patients with #AML. #amlsm #medicalcongress (@AML_Hub)
10 months ago
Clinical • HEOR
|
Venclexta (venetoclax)
10ms
Stellar talk from @AlexWaclawiczek from @hi_stem_lab on how AML LSC subtypes defined by mutation and differentiation status regulate response to Venetoclax. #EHA23 (@GhezziIan)
10 months ago
Venclexta (venetoclax)
10ms
#cll #EHA2023 Frustaci et al CPI-Venetoclax-Obinu for RT (MOLTO) N=28, RT mAge 70 1 prior LOT ORR 67%, CR 26% PFS median 8m OS 32m DOR 26m No TLS recorded (@MartinezCalleMD)
10 months ago
Venclexta (venetoclax)
10ms
UPDATED RESULTS OF VEN-A-QUI STUDY: A Ph 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR ND UNFIT AML PATIENTS: AZA OR L-D ARAC WITH VENETOCLAX AND QUIRZATINIB by Dr Juan Miguel Bergua @_pethema @sehh_es #AML #EHA2023 💪💪💪💪💪 (@noriega_dr)
10 months ago
Clinical
|
Venclexta (venetoclax)
10ms
CONGRESS #EHA2023 | @FadiHaddad_MD @MDAndersonNews discusses a phase II trial of mini-Hyper-CVD+venetoclax for pts with R/R Ph-ve ALL. N=23, 1 pt was in CR at enrollment. 55% responded to therapy, 9 in CR. ORR in 18 pts who had bone marrow assessment after CR =67%. #leusm #ALLsm (@ALL_Hub_)
10 months ago
Clinical • P2 data
|
Venclexta (venetoclax)
10ms
Congress | #EHA2023 | Poster @PratzKW @PennMedicine @PennCancer highlights an analysis of long-term outcomes post-allo-HSCT in older pts with AML treated with venetoclax + HMAs in a phase Ib trial and the phase III VIALE-A trial. Venetoclax + HMAs can be a bridge to allo-HSCT. (@AML_Hub)
10 months ago
Clinical • P3 data
|
Venclexta (venetoclax)
10ms
R/R T-ALL - is JAKinh+venetoclax or mTOR inh viable options going forward? Drug profiling upfront a powerful tool #EHA2023 #benchtobedside (@horne_gillian)
10 months ago
Venclexta (venetoclax)
10ms
Older and frail CLL patients treated with ibrutinib + venetoclax have a better PFS regardless of the MRD status than patients receiving chlorambucil + obinutuzumab. Ibrutinib + venetoclax should be the preferred regimen for this patient population @JCO_ASCO #CLL (@SLentzsch)
10 months ago
Clinical
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • Leukeran (chlorambucil)
10ms
When to IC or AZAVEN in AML fit patients? By @DanPollyea #EHA2023 (while waiting for RCT data) #leusm (@melmehdi)
10 months ago
Clinical
|
Venclexta (venetoclax) • azacitidine
10ms
Meant Venetoclax myeloma activity.. (@RenoHemonc)
10 months ago
Venclexta (venetoclax)
10ms
Dara myeloma activity from @rajshekharucms article How do we manage t(11;14) plasma cell disorders with venetoclax? https://t.co/FUE4GLkBKG (@RenoHemonc)
10 months ago
Venclexta (venetoclax)
10ms
CONGRESS |#ASCO23 @Daver_Leukemia @MDAndersonNews summarizes 2 expansion cohort studies investigating PVEK+AZA+VEN in first-line AML therapy and PVEK+magrolimab in patients with R/R AML. Previous studies have shown treatments to be well tolerated but require further study #AMLsm (@AML_Hub)
10 months ago
Clinical
|
Venclexta (venetoclax) • azacitidine • magrolimab (GS-4721)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login